Toyota|$17.89 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.37 (¥4,012)+1.31%▲ (in JPY terms)
SoftBank|$29.23 (¥4,622)+1.49%▲ (in JPY terms)
MUFG|$21.70 (¥3,431)+2.39%▲ (in JPY terms)
Keyence|$511.38 (¥80,860)-0.06%▼ (in JPY terms)
Nintendo|$55.12 (¥8,715)+0.40%▲ (in JPY terms)
NTT|$1.11 (¥176)-0.51%▼ (in JPY terms)
Takeda|$39.94 (¥6,315)+0.08%▲ (in JPY terms)
Tokyo Electron|$64.25 (¥10,160)+0.74%▲ (in JPY terms)
Recruit|$119.18 (¥18,845)+0.24%▲ (in JPY terms)
ITOCHU|$14.57 (¥2,304)+0.26%▲ (in JPY terms)
Honda|$11.41 (¥1,804)+0.00%▲ (in JPY terms)
Shin-Etsu|$37.20 (¥5,882)+0.22%▲ (in JPY terms)
Tokio Marine|$3.53 (¥559)+2.63%▲ (in JPY terms)
Fast Retailing|$475.65 (¥75,210)-0.20%▼ (in JPY terms)
Toyota|$17.89 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.37 (¥4,012)+1.31%▲ (in JPY terms)
SoftBank|$29.23 (¥4,622)+1.49%▲ (in JPY terms)
MUFG|$21.70 (¥3,431)+2.39%▲ (in JPY terms)
Keyence|$511.38 (¥80,860)-0.06%▼ (in JPY terms)
Nintendo|$55.12 (¥8,715)+0.40%▲ (in JPY terms)
NTT|$1.11 (¥176)-0.51%▼ (in JPY terms)
Takeda|$39.94 (¥6,315)+0.08%▲ (in JPY terms)
Tokyo Electron|$64.25 (¥10,160)+0.74%▲ (in JPY terms)
Recruit|$119.18 (¥18,845)+0.24%▲ (in JPY terms)
ITOCHU|$14.57 (¥2,304)+0.26%▲ (in JPY terms)
Honda|$11.41 (¥1,804)+0.00%▲ (in JPY terms)
Shin-Etsu|$37.20 (¥5,882)+0.22%▲ (in JPY terms)
Tokio Marine|$3.53 (¥559)+2.63%▲ (in JPY terms)
Fast Retailing|$475.65 (¥75,210)-0.20%▼ (in JPY terms)

Astellas Pharma Inc.

2026-06-24 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received approval in Europe for combination therapy with pembrolizumab for resectable muscle-invasive bladder cancer that is unsuitable for cisplatin, providing a new treatment option as adjuvant therapy before and after surgery.”

by

2026-06-24 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received a … 続きを読む

2026-05-22 Astellas Pharma Inc. “The European CHMP has adopted a recommendation for marketing authorization of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab for cisplatin-unsuitable resectable muscle-invasive bladder cancer.”

by

2026-05-22 Astellas Pharma Inc. “The European CHMP has adopted a recommendation for marketing authorizat … 続きを読む

2026-05-14 Astellas Pharma Inc. “An application for approval in Japan has been submitted for an additional indication for the antibody-drug conjugate Padsev™ (enfortumab vedotin) in combination with pembrolizumab for the treatment of muscle-invasive bladder cancer for which cisplatin is indicated.”

by

2026-05-14 Astellas Pharma Inc. “An application for approval in Japan has been submitted for an addition … 続きを読む

2026-04-21 Astellas Pharma Inc. “The FDA has accepted an application for approval of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab, regardless of whether cisplatin is indicated, as a neoadjuvant therapy for muscle-invasive bladder cancer, and has granted it priority review.”

by

2026-04-21 Astellas Pharma Inc. “The FDA has accepted an application for approval of the antibody-drug c … 続きを読む

Contact